Moving up the lines, AstraZeneca stakes another PhIII win for Lynparza as adjuvant breast cancer therapy
AstraZeneca and Merck are now fairly certain Lynparza works as an adjuvant therapy for BRCA-mutated high-risk HER2-negative early breast cancer.
That’s because the independent data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.